Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

2(67%)

Phase Distribution

Ph not_applicable

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 21 (33.3%)

N/A2 (66.7%)

Trials by Status

completed133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

terminatednot_applicable

Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up

NCT03172195

terminatednot_applicable

Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis

NCT03724929

completedphase_2

Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

NCT03182166

Clinical Trials (3)

Showing 3 of 3 trials

NCT03172195Not Applicable

Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up

Terminated

NCT03724929Not Applicable

Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis

Terminated

NCT03182166Phase 2

Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

Completed

All 3 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 3